Clinical cases for jaundice diabetes biochemistry MBBS

Reading File

Asking for Preferences

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have excellent source material from Goldman-Cecil Medicine, Schwartz's Surgery, Tietz Lab Medicine, and Harper's Biochemistry. Let me compile the full clinical cases.

Clinical Cases for MBBS - Biochemistry: Jaundice & Diabetes

SECTION 1: JAUNDICE CASES

Case 1 - Prehepatic (Hemolytic) Jaundice

Presenting Complaint

A 22-year-old male college student presents with yellowish discoloration of eyes and skin for 3 days. He reports passing dark urine. No abdominal pain, fever, or history of alcohol use. He has a cousin with a similar episode.

Physical Examination

Icteric sclerae, mild pallor
Splenomegaly (2 cm below costal margin)
No hepatomegaly, no ascites, no spider naevi

Investigations

Test	Result	Interpretation
Total bilirubin	5.8 mg/dL	Elevated
Direct (conjugated) bilirubin	0.6 mg/dL	Normal
Indirect (unconjugated) bilirubin	5.2 mg/dL	Markedly elevated
Urine bilirubin	Absent	Key finding
Urine urobilinogen	Markedly elevated	-
Hb	7.8 g/dL	Anaemia
Reticulocyte count	8%	Elevated (hemolysis)
Peripheral smear	Spherocytes, polychromasia	-
Direct Coombs test	Positive	Immune-mediated
LFTs (AST, ALT, ALP)	Near normal	Liver intact

Diagnosis: Autoimmune hemolytic anemia causing prehepatic jaundice

Biochemical Explanation

Excess red cell breakdown produces large amounts of unconjugated (indirect) bilirubin. This overwhelms the hepatocyte's conjugation system. Key points:

Unconjugated bilirubin is water-insoluble - bound to albumin in plasma - so it cannot be filtered by kidneys. Hence, no bilirubin in urine (acholuric jaundice).
Liver receives excess bilirubin, conjugates and excretes it as bile. This produces excess urobilinogen in the gut, absorbed back, and excreted in urine - hence urine urobilinogen is high.
Stools are dark (excess stercobilin).

"Dysfunction in any of the prehepatic, intrahepatic, or posthepatic phases can lead to jaundice." - Schwartz's Principles of Surgery, 11th Ed.

Case 2 - Hepatocellular Jaundice (Viral Hepatitis)

Presenting Complaint

A 19-year-old male presents with jaundice for 5 days. He had prodromal fatigue, nausea, anorexia, and low-grade fever for 2 weeks before jaundice appeared. He returned recently from a rural camp. He reports clay-colored stools and dark urine.

Physical Examination

Icterus ++, mild hepatomegaly (tender)
No splenomegaly, no ascites
Low-grade fever (38.1°C)

Investigations

Test	Result	Interpretation
Total bilirubin	9.2 mg/dL	Elevated
Direct bilirubin	6.4 mg/dL	Predominantly conjugated
Indirect bilirubin	2.8 mg/dL	Also elevated
Urine bilirubin	Positive (3+)	Conjugated leaks into urine
ALT	1840 U/L	Markedly elevated (hepatocellular damage)
AST	1240 U/L	Elevated, but ALT > AST
ALP	180 U/L	Mildly elevated
Prothrombin time	16 seconds (INR 1.4)	Mildly prolonged
Anti-HAV IgM	Positive
Urine urobilinogen	Initially absent, then present

Diagnosis: Acute Hepatitis A (hepatocellular jaundice)

Biochemical Explanation

Viral injury damages hepatocytes. The impaired liver cannot:

Take up bilirubin from blood
Conjugate it efficiently
Excrete conjugated bilirubin into bile

So both conjugated and unconjugated bilirubin rise. However, since conjugated bilirubin is water-soluble, it spills into urine - giving bilirubinuria (dark urine).

Why ALT > AST in viral hepatitis? ALT is cytoplasmic and highly specific for hepatocytes. It leaks early and selectively. AST is mitochondrial and elevates later. ALT:AST ratio >2 favors viral hepatitis; AST:ALT >2 suggests alcoholic hepatitis.

"In hepatocellular dysfunction caused by viral hepatitis, aminotransferase levels are elevated, with serum ALT higher than AST." - Goldman-Cecil Medicine

"ALT is considered more specific for liver disease than AST, because AST is elevated in cases of cardiac or skeletal muscle injury while ALT is not." - Harper's Illustrated Biochemistry, 32nd Ed.

Case 3 - Obstructive (Posthepatic) Jaundice

Presenting Complaint

A 55-year-old man presents with progressive yellowish discoloration of eyes for 3 weeks. He reports clay-colored (pale) stools, dark urine, and intense pruritus. He has lost 6 kg over 2 months. He is a smoker and has no prior liver disease. No fever, no abdominal pain.

Physical Examination

Deep jaundice (bilirubin clinically appears yellow-green)
Palpable, non-tender gallbladder (Courvoisier's sign)
Scratch marks over skin (pruritus)
No splenomegaly

Investigations

Test	Result	Interpretation
Total bilirubin	18 mg/dL	Markedly elevated
Direct bilirubin	15.8 mg/dL	Predominantly conjugated
ALP	680 U/L	Markedly elevated
GGT	420 U/L	Markedly elevated
ALT/AST	Mildly elevated (120/90 U/L)	Secondary hepatocellular damage
Urine bilirubin	4+	Bilirubinuria
Urine urobilinogen	Absent	Bile not reaching gut
Stool color	Pale/clay	Absent stercobilin
CA 19-9	Markedly elevated	Tumor marker
USG abdomen	Dilated CBD, dilated intrahepatic ducts, pancreatic head mass
CECT abdomen	Carcinoma head of pancreas

Diagnosis: Carcinoma head of pancreas causing obstructive (posthepatic) jaundice

Biochemical Explanation

Obstruction prevents bile (containing conjugated bilirubin) from reaching the duodenum:

Conjugated bilirubin backs up into blood - high direct bilirubin
It is water-soluble - appears in urine (bilirubinuria)
No bile in gut - no urobilinogen - pale stools, absent urine urobilinogen
ALP and GGT elevated (cholestatic pattern) due to bile duct pressure inducing enzyme synthesis in bile duct epithelial cells
Pruritus from bile salt deposition in skin

"In patients with biliary obstruction or cholestatic liver diseases, bilirubin and alkaline phosphatase levels are elevated." - Goldman-Cecil Medicine

Courvoisier's sign (palpable non-tender gallbladder + jaundice) = obstructive jaundice due to malignancy until proven otherwise.

Case 4 - Hereditary Unconjugated Hyperbilirubinemia

Presenting Complaint

A 24-year-old medical student is incidentally found to have yellow eyes during a medical college physical examination. He had similar episodes during exams and after prolonged fasting. He denies any abdominal symptoms, fever, or dark urine. His father also has "yellow eyes."

Investigations

Test	Result
Total bilirubin	3.2 mg/dL
Direct bilirubin	0.3 mg/dL
Indirect bilirubin	2.9 mg/dL
LFTs (AST, ALT, ALP, albumin)	All normal
Hb, reticulocyte count, peripheral smear	Normal
Urine bilirubin	Absent
Urine urobilinogen	Normal

Diagnosis: Gilbert's Syndrome

Discussion

Gilbert's syndrome is a benign genetic condition with reduced UGT1A1 (UDP-glucuronosyltransferase) enzyme activity - reducing conjugation of bilirubin by ~30%. Key features:

Autosomal recessive (TA repeat polymorphism in UGT1A1 promoter)
Mild unconjugated hyperbilirubinemia triggered by fasting, illness, stress, exercise
Completely benign - no treatment required
Differentiated from hemolysis by: normal Hb, normal reticulocytes, no splenomegaly

"Gilbert's syndrome is a genetic variant characterized by diminished activity of the enzyme glucuronyltransferase... It is a benign condition that affects approximately 4% to 7% of the population. Typically, the disease results in transient mild increases in unconjugated bilirubin levels and jaundice during episodes of fasting, stress, or illness." - Schwartz's Principles of Surgery, 11th Ed.

Jaundice Biochemistry Summary Table

Feature	Prehepatic	Hepatocellular	Posthepatic
Serum bilirubin	Unconjugated (indirect) ↑↑	Both ↑	Conjugated (direct) ↑↑
Urine bilirubin	Absent	Present	Present (4+)
Urine urobilinogen	↑↑↑	Variable	Absent
Stool color	Dark	Normal/pale	Pale/clay
ALT/AST	Normal	↑↑↑ (ALT>AST in viral)	Mildly ↑
ALP	Normal	Mild ↑	↑↑↑
Prothrombin time	Normal	Prolonged	Prolonged (Vit K malabsorption)
Cause	Hemolysis, Gilbert's	Viral hepatitis, drugs, alcohol	Gallstones, Ca pancreas

SECTION 2: DIABETES MELLITUS CASES

Case 5 - Type 1 Diabetes Mellitus - New Onset

Presenting Complaint

A 14-year-old girl presents with 4 weeks of polyuria, polydipsia, and polyphagia. She has lost 5 kg despite eating well. Her mother noticed she has been unusually tired. Today she is drowsy with rapid deep breathing.

Physical Examination

BMI: 17 kg/m² (thin)
BP: 90/60 mmHg (postural drop)
HR: 122/min (tachycardia)
Respiratory rate: 28/min, Kussmaul breathing (deep, rapid, sighing)
Fruity/acetone odor on breath
Dry mucous membranes, reduced skin turgor

Investigations

Test	Result
Random blood glucose	520 mg/dL
Serum sodium	128 mEq/L (pseudohyponatremia)
Serum potassium	5.4 mEq/L (initially high, total body deficit)
Serum bicarbonate	10 mEq/L (↓↓)
Arterial pH	7.16 (acidosis)
Anion gap	22 mEq/L (↑, wide-gap metabolic acidosis)
Serum ketones (beta-hydroxybutyrate)	Strongly positive
Urine: glucose 4+, ketones 4+	-
HbA1c	11.2%
C-peptide	Very low
Anti-GAD antibody	Positive

Diagnosis: New-onset Type 1 DM presenting with Diabetic Ketoacidosis (DKA)

Biochemical Pathogenesis of DKA

Absent insulin → 3 key consequences:

Hyperglycemia: No glucose uptake into cells → hyperglycemia → osmotic diuresis → polyuria → dehydration → pseudohyponatremia
Ketogenesis: Glucagon dominates → activates hormone-sensitive lipase → free fatty acids (FFAs) released from adipose → FFAs go to liver → beta-oxidation → excess acetyl-CoA → ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone) → metabolic acidosis
Protein catabolism: Muscle proteolysis → gluconeogenic amino acids → more hyperglycemia

Kussmaul breathing is the body's respiratory compensation for metabolic acidosis - hyperventilation blows off CO₂ to raise pH.

"The clinical history of DKA typically involves deterioration during several hours to days, with progressive polyuria, polydipsia... physical findings... include dry skin and mucous membranes, reduced jugular venous pressure, tachycardia, orthostatic hypotension, depressed mental function sometimes with frank coma, and deep, rapid respirations (Kussmaul breathing)." - Goldman-Cecil Medicine

DKA Diagnostic Criteria:

Blood glucose: variable (often >250 mg/dL, can occasionally be near-normal in "euglycemic DKA")
Serum bicarbonate: <18 mmol/L
Arterial pH: <7.3 (mild: 7.20-7.30; severe: <7.00)
Ketonemia/ketonuria: positive

"The diagnosis of diabetic ketoacidosis is based on the presence of hyperglycemia, ketosis, and acidosis." - Goldman-Cecil Medicine

Case 6 - Type 2 Diabetes Mellitus - Incidental Detection

Presenting Complaint

A 52-year-old obese man comes for routine check-up. He has no specific complaints but admits to "feeling tired and urinating frequently at night." He has hypertension on amlodipine. Father had diabetes. No polyuria, no weight loss. BMI: 29 kg/m².

Examination

BP 148/92 mmHg
BMI 29 kg/m², waist circumference 98 cm (abdominal obesity)
Acanthosis nigricans at neck and axillae
Fundus: no retinopathy yet

Investigations

Test	Result	Reference
Fasting plasma glucose (×2)	148 mg/dL	Diagnostic if ≥126 mg/dL
2-hour OGTT (75g)	230 mg/dL	Diagnostic if ≥200 mg/dL
HbA1c	8.1%	Diagnostic if ≥6.5%
Fasting insulin	High	Insulin resistance
Urinary microalbumin/creatinine	38 mg/g	Early nephropathy
Total cholesterol	236 mg/dL	Dyslipidemia
TG	290 mg/dL, HDL 32 mg/dL	Metabolic syndrome

Diagnosis: Type 2 Diabetes Mellitus with early nephropathy; Metabolic Syndrome

Discussion - Biochemical Basis

Acanthosis nigricans is a skin marker of insulin resistance - excess insulin stimulates keratinocyte and fibroblast growth via IGF-1 receptors.

ADA Diagnostic Criteria for Diabetes:

FPG ≥126 mg/dL (7.0 mmol/L) on 2 occasions
2-hr plasma glucose ≥200 mg/dL during 75g OGTT
HbA1c ≥6.5%
Random plasma glucose ≥200 mg/dL with symptoms

"HbA1c ≥6.5% was selected as the decision point... HbA1c concentrations 5.7 to 6.4% indicate subjects at high risk of developing diabetes." - Tietz Textbook of Laboratory Medicine, 7th Ed.

HbA1c Biochemistry: Glucose attaches non-enzymatically to the N-terminal valine of the beta chain of HbA (glycation). The HbA1c level reflects average blood glucose over the preceding 8-12 weeks (the lifespan of RBCs). Formula: estimated average glucose (eAG) = (28.7 × HbA1c) - 46.7 mg/dL.

Case 7 - Hyperosmolar Hyperglycemic State (HHS)

Presenting Complaint

A 70-year-old man with known Type 2 DM on oral medications is brought in confused and lethargic. His family says he had poor oral intake and vomiting for 5 days due to a gastroenteritis. He has not taken his medications for 3 days.

Examination

GCS: 11/15 (E3V3M5)
Severe dehydration: sunken eyes, absent skin turgor, dry tongue
BP: 85/60 mmHg, HR: 128/min
No Kussmaul breathing, no fruity odor

Investigations

Test	Result
Blood glucose	810 mg/dL
Serum sodium	155 mEq/L
Serum osmolality	370 mOsm/kg (>320 = hyperosmolar)
Serum bicarbonate	20 mEq/L (near normal)
Arterial pH	7.36 (normal!)
Serum ketones	Trace/absent
BUN/Creatinine	62/3.2 mg/dL (prerenal AKI)

Diagnosis: Hyperosmolar Hyperglycemic State (HHS)

DKA vs HHS Comparison:

Feature	DKA	HHS
Type of DM	Usually Type 1	Usually Type 2
Age	Younger	Older
Glucose	250-600 mg/dL	>600 mg/dL (often >800)
Ketones	Marked	Absent/trace
pH	<7.3	Normal
Serum HCO3	<18 mEq/L	Normal
Serum osmolality	<320 mOsm/kg	>320 mOsm/kg
Onset	Hours-days	Days-weeks
Mortality	~1-5%	~10-20%

Why no ketosis in HHS? In Type 2 DM, residual insulin secretion is enough to suppress lipolysis and ketogenesis, but insufficient to prevent hyperglycemia. In DKA (Type 1), no insulin at all - unrestrained lipolysis drives ketone production.

"In the hyperosmolar hyperglycemic state, the clinical severity and levels of consciousness generally correlate with the severity and duration of hyperosmolarity. Up to 10% of patients present with frank coma." - Goldman-Cecil Medicine

SECTION 3: BIOCHEMISTRY INTEGRATION CASES

Case 8 - Diabetes with Jaundice (Integration Case)

Presenting Complaint

A 45-year-old man with Type 2 DM on metformin and a statin presents with jaundice for 10 days. He started a new herbal supplement 3 weeks ago. He has no fever, no abdominal pain, no change in stools.

Investigations

Test	Result
Total bilirubin	7.2 mg/dL
Direct bilirubin	5.8 mg/dL
ALT	960 U/L
ALP	280 U/L
INR	1.9
Viral hepatitis screen (A, B, C, E)	Negative
Autoimmune markers	Negative
USG abdomen	Normal liver, no ductal dilatation
HbA1c	9.8% (poorly controlled)

Diagnosis: Drug-induced liver injury (DILI) from herbal supplement causing hepatocellular jaundice

Teaching Points

Diabetics are at higher risk of non-alcoholic fatty liver disease (NAFLD) and drug hepatotoxicity
Always take a thorough drug/supplement history in any patient with jaundice
Herbal supplements are a common but under-reported cause of DILI
Poor glycemic control (HbA1c 9.8%) suggests longstanding hyperglycemia promoting hepatic steatosis as a background factor
Biochemically: Hepatocellular pattern (ALT>>ALP); both conjugated and unconjugated bilirubin elevated; impaired synthetic function (raised INR)

Case 9 - Lactic Acidosis in a Diabetic Patient

Presenting Complaint

A 58-year-old man with Type 2 DM on metformin 2g/day presents with sudden breathlessness, confusion, and abdominal pain. He was recently started on an iodinated contrast agent for a CT scan. He has chronic kidney disease (CKD Stage 3, eGFR 28 mL/min).

Investigations

Test	Result
Blood glucose	180 mg/dL (mild)
Arterial pH	7.08
Serum bicarbonate	8 mEq/L
Lactate	14 mmol/L (normal <2)
Anion gap	28 mEq/L
Serum ketones	Absent
Creatinine	4.8 mg/dL (AKI on CKD)

Diagnosis: Metformin-associated lactic acidosis (MALA)

Biochemical Mechanism: Metformin inhibits mitochondrial complex I (NADH dehydrogenase), reducing oxidative phosphorylation. Pyruvate cannot enter the TCA cycle efficiently → accumulates → converted to lactate (anaerobic glycolysis). In renal failure, metformin accumulates (it is renally excreted), worsening the effect. Contrast-induced nephropathy is a precipitant.

Key rule: Metformin is contraindicated when eGFR <30 mL/min and should be withheld before contrast procedures.

Biochemistry Quick Reference for MBBS Exams

Bilirubin Pathway in Brief

Heme (from Hb breakdown) → biliverdin (via heme oxygenase) → bilirubin (via biliverdin reductase)
Unconjugated bilirubin + albumin → liver
Hepatocyte: UDP-glucuronosyltransferase → bilirubin glucuronide (conjugated, water-soluble)
Secreted into bile → intestine → urobilinogen (by gut bacteria) → stercobilinogen → stercobilin (brown stool)
Some urobilinogen reabsorbed → portal vein → liver (enterohepatic circulation) → small amount excreted by kidney → urine urobilinogen

Insulin and Glucose Homeostasis in Brief

Post-meal: Glucose ↑ → insulin ↑ → glycogen synthesis, glucose uptake, protein synthesis, lipogenesis; glucagon ↓
Fasting: Glucose ↓ → glucagon ↑, insulin ↓ → glycogenolysis, gluconeogenesis, lipolysis, ketogenesis
Type 1 DM: Autoimmune (anti-GAD, anti-IA2 antibodies) destruction of beta cells → absolute insulin deficiency → DKA
Type 2 DM: Insulin resistance + progressive beta cell failure → relative deficiency → HHS, no ketosis

Sources:

Goldman-Cecil Medicine (International Ed.), Chapters 133 & 210
Schwartz's Principles of Surgery, 11th Ed., Chapter on Liver/Biliary
Harper's Illustrated Biochemistry, 32nd Ed., Chapter on LFTs
Tietz Textbook of Laboratory Medicine, 7th Ed., Chapters 47 & 51

For 1st and 2nd year too

Finding Sources

Reading File

Finding Sources

Reading File

Excellent material from Harrison's (2025), Medical Physiology, and Tietz. Now let me compile the 1st and 2nd year-focused cases.

Clinical Cases for 1st & 2nd Year MBBS

Biochemistry & Physiology Focus - Jaundice and Diabetes

PART A: JAUNDICE - 1ST & 2ND YEAR CASES

CASE J1 - "The Biochemistry Behind Yellow Eyes"

(Focuses on: Bilirubin Formation, Conjugation Pathway - 1st Year Biochemistry)

Vignette

A 20-year-old male presents to the college health center with yellow discoloration of the eyes. He is otherwise healthy, has no abdominal complaints, and the episode appeared after he skipped meals during exam week.

Examination: Mild icteric sclerae only. No pallor, no hepatomegaly, no lymphadenopathy.

Labs:

Total bilirubin: 3.1 mg/dL
Direct bilirubin: 0.2 mg/dL (indirect = 2.9 mg/dL)
LFTs, CBC: all normal
Urine bilirubin: absent

The Biochemistry Story

This is Gilbert's syndrome - the perfect case to teach the complete bilirubin pathway:

Step 1 - Where does bilirubin come from?

Old red blood cells (RBC lifespan ~120 days) are broken down in the reticuloendothelial system (spleen, liver, bone marrow):

Hemoglobin
    ↓  (globin released; heme extracted)
Heme (ferroprotoporphyrin IX)
    ↓  heme oxygenase (ER of macrophages)
    ↓  → CO released + Fe²⁺ released (recycled)
Biliverdin (green pigment)
    ↓  biliverdin reductase (cytosol)
Bilirubin (yellow-orange pigment)

"About 80-85% of the 4 mg/kg body weight of bilirubin produced each day is derived from the breakdown of hemoglobin in senescent red blood cells. The remainder comes from prematurely destroyed erythroid cells in bone marrow and from the turnover of hemoproteins such as myoglobin and cytochromes." - Harrison's Principles of Internal Medicine, 22nd Ed (2025)

Key fact for viva: CO released = one molecule per heme molecule. This is clinically measurable in breath CO tests of hemolysis.

Step 2 - Transport in blood

Bilirubin is water-insoluble (lipophilic) due to internal hydrogen bonding between its propionic acid groups and the imino/lactam groups of the opposite dipyrrolic half. It is called unconjugated (indirect) bilirubin.

It binds non-covalently to albumin for transport in blood to the liver.

"To be transported in blood, bilirubin must be solubilized. Solubilization is accomplished by the reversible, noncovalent binding of bilirubin to albumin." - Harrison's, 22nd Ed.

Why can't unconjugated bilirubin appear in urine? It is protein-bound and lipophilic - cannot be filtered by glomeruli. Therefore: no bilirubin in urine in prehepatic/unconjugated jaundice.

Step 3 - Hepatic uptake and conjugation

In hepatocytes:

Bilirubin separated from albumin at sinusoidal membrane
Taken up by carrier-mediated transport (OATP transporters)
Bound intracellularly to ligandin (glutathione-S-transferase family proteins) to prevent back-diffusion
In smooth endoplasmic reticulum: conjugated with glucuronic acid

Key enzyme: UDP-glucuronosyltransferase (UGT1A1)

Bilirubin + UDP-glucuronic acid  →  Bilirubin monoglucuronide
                    → further  →  Bilirubin diglucuronide
                                   (water-soluble = CONJUGATED bilirubin)

In Gilbert's syndrome: UGT1A1 activity is reduced ~30% (TA-repeat polymorphism in UGT1A1 promoter gene). During fasting, free fatty acids compete for albumin binding and displace bilirubin - so more unconjugated bilirubin floods the hepatocyte, overwhelming the reduced enzyme.

Step 4 - Excretion and fate in the gut

Conjugated bilirubin → excreted via MRP2 transporter → bile canaliculi → bile ducts → duodenum

In the intestine:

Conjugated bilirubin
    ↓  bacterial β-glucuronidases (distal ileum/colon)
Unconjugated bilirubin
    ↓  gut bacterial reduction
Urobilinogens (colorless)
    ↓  oxidation in stool
Stercobilin (brown color of stool)

Enterohepatic circulation: ~10-20% of urobilinogens reabsorbed → portal blood → liver (mostly re-excreted) → small fraction in urine as urobilinogen (normal ≤1 mg/dL in urine).

The Van den Bergh Reaction (Exam Favorite)

This lab test distinguishes direct vs indirect bilirubin:

Direct reaction (no accelerator): Conjugated bilirubin reacts directly with diazo reagent (diazotized sulfanilic acid) → purple color
Indirect reaction (add alcohol as accelerator): Unconjugated bilirubin reacts after alcohol disrupts albumin-binding

"The direct fraction provides an approximation of the conjugated bilirubin level in serum." - Harrison's, 22nd Ed.

Normal values: Total bilirubin 0.2-1.0 mg/dL; Direct <0.3 mg/dL; Indirect <0.7 mg/dL. Jaundice clinically visible when >3 mg/dL.

CASE J2 - "The Jaundiced Newborn"

(Focuses on: Neonatal Jaundice, Kernicterus, Physiological vs Pathological - 1st/2nd Year)

Vignette

A 3-day-old full-term male baby develops yellowish discoloration. Born by normal vaginal delivery. Mother is O positive, baby is A positive. Jaundice first noted on day 2, now on day 3, extending to the chest. Baby is breastfeeding well. No lethargy, no refusal to feed.

Examination: Icteric sclerae + face + chest. Kramer's zone II-III. No pallor, no hepatosplenomegaly.

Labs:

Total serum bilirubin: 12 mg/dL (Day 3)
Direct bilirubin: 0.4 mg/dL
Coombs test (DCT): Negative
Hb: 16 g/dL (normal for newborn)

Diagnosis: Physiological jaundice of the newborn

Why does physiological jaundice occur? (1st Year Biochemistry)

High rate of RBC breakdown - fetal RBCs have shorter lifespan (70-90 days) and are replaced by adult RBCs postnatally. Massive bilirubin load.
Immature UGT1A1 enzyme - neonatal hepatic UDP-glucuronosyltransferase is only ~1% of adult activity at birth, reaching adult levels by ~4-8 weeks. Cannot conjugate the excess bilirubin.
High enterohepatic circulation - neonatal gut has:
- High beta-glucuronidase activity (deconjugates bilirubin back)
- Sterile gut initially (no bacteria to convert to urobilinogen)
- Slow gut motility → more reabsorption of unconjugated bilirubin
Low albumin - reduced binding capacity, more free bilirubin circulates

Why is unconjugated bilirubin dangerous in neonates? - Kernicterus

Unconjugated bilirubin (lipophilic + not bound to albumin = "free bilirubin") can cross the blood-brain barrier (BBB). In neonates, BBB is immature. It deposits in:

Basal ganglia (globus pallidus)
Cochlear nuclei
Cerebellum

→ Irreversible neurological damage = Kernicterus (kern = nucleus in German, icterus = jaundice)

Clinical features of kernicterus: opisthotonos, high-pitched cry, hearing loss, choreoathetosis, intellectual disability.

Treatment threshold: Phototherapy converts bilirubin to water-soluble photoisomers (lumirubin) that can be excreted in bile/urine without conjugation. Exchange transfusion for very high levels.

Physiological vs Pathological Neonatal Jaundice

Feature	Physiological	Pathological
Onset	Day 2-3	Within 24 hours
Duration	Resolves by day 7-10	Persists >14 days
Rate of rise	<5 mg/dL/day	>5 mg/dL/day
Bilirubin type	Unconjugated	May be conjugated (always pathological)
Cause	Normal physiology	Hemolysis, infection, metabolic

CASE J3 - "Obstructive Jaundice - The Biochemistry of Pale Stools"

(Focuses on: What happens when bile is blocked - 2nd Year)

Vignette

A 40-year-old obese woman presents with sudden onset severe right upper quadrant colicky pain, fever (39°C), and jaundice (Charcot's triad). She had similar but milder episodes before. Urine is cola-colored, stools are pale.

Labs:

Total bilirubin: 11 mg/dL; Direct: 9.5 mg/dL
ALP: 520 U/L; GGT: 390 U/L
ALT/AST: mildly elevated (180/120 U/L)
WBC: 16,000 (neutrophilia)
Urine bilirubin: 4+; Urine urobilinogen: absent
USG: Cholelithiasis, dilated CBD 12 mm, stone at CBD

Diagnosis: Choledocholithiasis with ascending cholangitis (obstructive jaundice)

Biochemistry: Why are the stools pale and urine dark?

Normal bile flow:

Conjugated bilirubin → bile → intestine → urobilinogen → stercobilin → BROWN STOOL
                                             ↓ (enterohepatic)
                                         kidney → urobilinogen in urine (trace)

When CBD is blocked:

Conjugated bilirubin CANNOT reach intestine:
  → Backs up into liver → sinusoids → bloodstream (high direct bilirubin)
  → Spills into urine (water-soluble) → DARK URINE (bilirubinuria)
  → No urobilinogen formed in gut → NO UROBILINOGEN IN URINE
  → No stercobilin → PALE/CLAY-COLORED STOOLS

Why ALP is elevated in obstruction?

Bile acids and bilirubin under back-pressure induce synthesis of alkaline phosphatase (ALP) in the bile duct epithelial cells (cholangiocytes). ALP is also solubilized from hepatocyte canalicular membranes by bile acids. GGT rises for the same reason. ALP elevation >3× normal with raised bilirubin and minimal aminotransferase rise = cholestatic pattern.

Why does pruritus occur? Bile salts deposit in skin, stimulating cutaneous nerve endings.

Why is PT prolonged in obstructive jaundice? Bile is required for absorption of fat-soluble vitamins (A, D, E, K). Vitamin K is essential for activation (gamma-carboxylation) of clotting factors II, VII, IX, X by carboxylase enzyme. Block in bile → Vitamin K deficiency → prolonged PT. (This corrects with parenteral Vit K - distinguishes from hepatocellular cause where PT does not correct.)

PART B: DIABETES - 1ST & 2ND YEAR CASES

CASE D1 - "Insulin: From Gene to Granule"

(Focuses on: Insulin Biosynthesis - 1st Year Biochemistry)

Vignette

A 16-year-old boy with newly diagnosed Type 1 DM is being counseled by his doctor. His mother asks: "How is insulin normally made in the body, and why is my son's body not making it?"

Insulin Biosynthesis - Step by Step

Gene: Insulin gene located on short arm of chromosome 11

Transcription in beta cell nucleus
         ↓
mRNA: encodes PREPROINSULIN (110 amino acids)
         ↓ translation on ribosomes
Preproinsulin enters rough ER
         ↓ signal peptidase cleaves 24-amino-acid leader (signal) sequence in ER lumen
PROINSULIN (86 amino acids) = B chain + C peptide + A chain (linear)
         ↓ transported to Golgi
3 disulfide bonds form (A6-A11, A7-B7, A20-B19)
         ↓ packaged in secretory granules
         ↓ specific proteases (PC1/3 and PC2) cleave at 2 sites
Insulin (51 amino acids) + C-peptide (31 amino acids)

"Insulin is initially synthesized as a single-chain 86-amino-acid precursor polypeptide, preproinsulin. Subsequent proteolytic processing removes the amino-terminal signal peptide, giving rise to proinsulin. Cleavage of an internal 31-residue fragment from proinsulin generates C-peptide with the A (21 amino acids) and B (30 amino acids) chains of insulin connected by disulfide bonds." - Harrison's, 22nd Ed. (2025)

Final insulin: A-chain (21 aa) + B-chain (30 aa) joined by 2 disulfide bonds between chains + 1 intrachain disulfide in A chain. Total: 51 amino acids.

C-peptide clinical use:

Secreted in 1:1 molar ratio with insulin
Longer half-life than insulin (cleared more slowly)
Used to measure endogenous insulin secretion
In Type 1 DM: C-peptide is very low/absent (beta cells destroyed)
In Type 2 DM: C-peptide initially normal or high (insulin resistance)
Helps distinguish: exogenous insulin injection (C-peptide low, insulin high) vs insulinoma (both C-peptide and insulin high)

Why is C-peptide not insulin-like? C-peptide has no confirmed receptor and essentially no metabolic activity.

CASE D2 - "Glucose Knocks on the Door - Insulin Secretion Mechanism"

(Focuses on: Beta Cell Physiology, Ion Channels, Sulfonylurea MOA - 2nd Year)

Vignette

A 58-year-old Type 2 DM patient is started on glibenclamide (a sulfonylurea). Explain to the patient how glucose normally triggers insulin release, and how his tablet helps.

The Glucose-Insulin Secretion Cascade

Glucose rises (post-meal) in blood
         ↓
Enters beta cell via GLUT2 transporter (GLUT1 in humans) - not insulin-dependent
         ↓
Phosphorylated by GLUCOKINASE (the "glucose sensor") → Glucose-6-phosphate
         ↓  glycolysis + oxidative phosphorylation
ATP generated → ATP:ADP ratio rises
         ↓
ATP-sensitive K⁺ channel (K_ATP channel) CLOSES
         ↓
K⁺ cannot leave → membrane depolarizes (from -70mV toward 0)
         ↓
Voltage-gated Ca²⁺ channels OPEN
         ↓
Ca²⁺ influx into beta cell
         ↓
Triggers fusion of secretory granules with plasma membrane
         ↓
INSULIN (+ C-peptide + proinsulin) released by EXOCYTOSIS

"Glucose phosphorylation by glucokinase is the rate-limiting step that controls glucose-regulated insulin secretion. Further metabolism of glucose-6-phosphate via glycolysis generates ATP, which inhibits the activity of an ATP-sensitive K+ channel... Inhibition of this K+ channel induces beta cell membrane depolarization, which opens voltage-dependent calcium channels (leading to an influx of calcium) and stimulates insulin secretion." - Harrison's, 22nd Ed. (2025)

How do sulfonylureas work? Sulfonylureas (glibenclamide, glipizide, gliclazide) directly bind to the SUR1 subunit of the K_ATP channel and keep it closed - mimicking the effect of ATP. This causes depolarization → Ca²⁺ influx → insulin release regardless of blood glucose level. This is why they can cause hypoglycemia even if glucose is normal (unlike metformin).

Two-Phase Insulin Secretion

Phase	Timing	Source
First phase	0-10 min (rapid spike)	Pre-formed granules already docked at membrane
Second phase	10-60 min (sustained)	Newly synthesized + mobilized granules

In Type 2 DM: First-phase insulin secretion is lost early - one of the earliest detectable abnormalities. This causes the post-meal glucose spike that eventually damages blood vessels.

CASE D3 - "Where Does Glucose Go? - Insulin's Metabolic Actions"

(Focuses on: GLUT4, Glycolysis, Glycogen Synthesis, Lipogenesis - 2nd Year Biochemistry)

Vignette

A 2nd-year MBBS student asks: "After a rice meal, glucose rises. Insulin is released. Then what exactly happens biochemically in each tissue?"

Tissue-by-Tissue Actions of Insulin

Skeletal Muscle and Adipose Tissue:

Insulin → activates insulin receptor (tyrosine kinase receptor) → phosphorylates IRS-1/IRS-2
PI3K-Akt pathway activated → vesicles containing GLUT4 transporters migrate to cell membrane
GLUT4 insertion into membrane → glucose enters cell
GLUT4 is insulin-dependent (unlike GLUT1/GLUT2/GLUT3 which are constitutive)

In muscle: Glucose → glycolysis (ATP production) + glycogen synthesis (via glycogen synthase, activated by insulin through Akt phosphorylating and inactivating GSK-3)

In liver: Insulin → inhibits glycogenolysis + gluconeogenesis + promotes glycogen synthesis and glycolysis. Activates glucokinase (enzyme that phosphorylates glucose at high concentrations).

In adipose tissue: Glucose → glycerol-3-phosphate + fatty acids (lipogenesis) → stored as triglycerides. Insulin simultaneously inhibits hormone-sensitive lipase (HSL) - stopping lipolysis.

What happens in insulin deficiency (Type 1 DM or DKA)?

Process	Normal (Insulin Present)	DKA (No Insulin)
Glucose uptake (muscle/fat)	Via GLUT4 - active	BLOCKED (no GLUT4 translocation)
Liver glycogenolysis	Suppressed	Activated by glucagon
Gluconeogenesis	Suppressed	Activated (uses amino acids, glycerol)
Lipolysis (adipose)	Inhibited by insulin	Unrestrained - FFAs flood liver
Ketogenesis (liver)	Minimal	Massive (excess acetyl-CoA)

CASE D4 - "The Biochemistry of DKA"

(Focuses on: Ketone Body Formation, Anion Gap, Acid-Base - 2nd Year)

Vignette

A 14-year-old girl is brought in drowsy with fruity breath and deep rapid breathing. Blood glucose 480 mg/dL, pH 7.18, HCO₃ 9 mEq/L, Na 130, Cl 96. She has not taken insulin for 2 days.

Calculate the Anion Gap: AG = Na⁺ - (Cl⁻ + HCO₃⁻) = 130 - (96 + 9) = 25 mEq/L (elevated - normal is 8-12)

This is a high anion gap metabolic acidosis - the "missing" anions are ketoacids (acetoacetate and beta-hydroxybutyrate).

Ketone Body Biochemistry - The Full Pathway

Trigger: No insulin → glucagon dominates → activates hormone-sensitive lipase in adipose

Triglycerides (adipose)
    ↓  Hormone-sensitive lipase (activated by glucagon)
Glycerol + Free Fatty Acids (FFAs)
    ↓  FFAs enter liver
    ↓  Carnitine shuttle (carnitine acyltransferase I) - transfers FFA into mitochondria
Beta-oxidation → Acetyl-CoA generated MASSIVELY

Why can't acetyl-CoA enter TCA cycle normally in DKA?

Oxaloacetate (OAA) is depleted because:
- Pyruvate (the precursor of OAA) is being diverted to gluconeogenesis
- OAA itself is used in gluconeogenesis via PEPCK
Without OAA, acetyl-CoA cannot condense to form citrate → TCA blocked

Acetyl-CoA overflow → Ketogenesis:

2 × Acetyl-CoA → Acetoacetyl-CoA
                ↓  (+Acetyl-CoA via HMG-CoA synthase)
              HMG-CoA (in mitochondria)
                ↓  HMG-CoA lyase
         Acetoacetate + Acetyl-CoA

Acetoacetate  →  β-hydroxybutyrate (via beta-hydroxybutyrate dehydrogenase; NADH-dependent)
Acetoacetate  →  Acetone + CO₂ (spontaneous decarboxylation) ← fruity breath!

"The abundance of acetyl-CoA results from excessive mobilization of fatty acids from adipose tissue and their conversion by β-oxidation in the liver. The resulting excess acetyl-CoA is diverted to an alternative pathway in the mitochondria to form acetoacetic acid, β-hydroxybutyric acid, and acetone - three compounds known collectively as ketone bodies." - Tietz Textbook of Laboratory Medicine, 7th Ed.

Why does the liver produce ketones but cannot use them?

The liver lacks 3-ketoacid CoA transferase (thiophorase) - the enzyme needed to activate acetoacetate back to acetoacetyl-CoA for oxidation. So the liver makes ketones and ships them out for peripheral tissues (muscle, brain in starvation) to use as fuel.

How does insulin reverse DKA?

Insulin given IV
    ↓
Glucose uptake restored → OAA production restored
    ↓
Acetyl-CoA enters TCA cycle normally → ketogenesis stops
    ↓
Lipolysis suppressed → FFA supply to liver decreases
    ↓
Ketone bodies consumed faster than produced → ketoacidosis resolves

CASE D5 - "HbA1c - A Glycated Memory"

(Focuses on: Non-enzymatic Glycosylation, Amadori Product - 1st/2nd Year Biochemistry)

Vignette

A 2nd-year student asks: "How does HbA1c actually form? Why does it reflect 3 months of glucose control and not just today's blood sugar?"

Mechanism of HbA1c Formation

HbA1c forms by non-enzymatic glycosylation (glycation) - glucose attaches to proteins spontaneously without any enzyme.

Step 1 - Schiff base (Aldimine):
Glucose (aldehyde group) + NH₂ terminal valine of Hb beta chain
    → Unstable Schiff base (forms within hours, reversible)

Step 2 - Amadori product:
Schiff base undergoes Amadori rearrangement
    → Stable ketoamine (HbA1c) - this is IRREVERSIBLE once formed

Key facts:

Rate of HbA1c formation is directly proportional to blood glucose concentration (mass action)
HbA1c persists for the entire lifespan of the RBC (~120 days)
It reflects the weighted average of blood glucose over 8-12 weeks (recent weeks contribute more than earlier weeks due to RBC age distribution)

Conditions that falsely lower HbA1c:

Hemolytic anemia (RBCs destroyed before glycation accumulates)
Blood transfusion (new donor RBCs)
Pregnancy (increased RBC turnover)
Hemoglobin variants (HbS, HbC interfere with some assays)

Conditions that falsely raise HbA1c:

Iron deficiency anemia (older RBCs accumulate = more time for glycation)
Asplenia

"An HbA1c value ≥6.5% was selected as the diagnostic decision point, based on the prevalence of retinopathy." - Tietz Textbook of Laboratory Medicine, 7th Ed.

Quick Reference: MBBS Exam Must-Know Points

Bilirubin

Fact	Answer
Enzyme making bilirubin from heme	Heme oxygenase (then biliverdin reductase)
% bilirubin from RBC breakdown	80-85%
Key conjugating enzyme in liver	UGT1A1 (UDP-glucuronosyltransferase)
Normal serum bilirubin	0.2-1.0 mg/dL
Jaundice clinically visible at	>3 mg/dL
Deficient enzyme in Gilbert's	UGT1A1 (30% reduced)
Deficient enzyme in Crigler-Najjar Type 1	UGT1A1 (completely absent)
Why pale stools in obstruction	No bile → no stercobilin
Why dark urine in obstruction	Water-soluble conjugated bilirubin in urine
Van den Bergh direct reaction tests	Conjugated (direct) bilirubin

Insulin & Diabetes

Fact	Answer
Insulin gene location	Chromosome 11 short arm
Precursor chain	Preproinsulin (110 aa) → Proinsulin (86 aa) → Insulin (51 aa)
A chain amino acids	21
B chain amino acids	30
Glucose sensor enzyme in beta cell	Glucokinase
Channel closed by insulin stimulus	K_ATP channel (K⁺ channel)
Sulfonylurea binding site	SUR1 subunit of K_ATP channel
GLUT4 is found in	Muscle and adipose (insulin-dependent)
Ketone bodies (3 types)	Acetoacetate, Beta-hydroxybutyrate, Acetone
Enzyme making HMG-CoA	HMG-CoA synthase (mitochondrial)
Why liver can't use ketones	Lacks 3-ketoacid CoA transferase
HbA1c diagnostic cut-off	≥6.5%
HbA1c reflects glucose over	8-12 weeks (RBC lifespan)
C-peptide clinical use	Marker of endogenous insulin secretion

Sources:

Harrison's Principles of Internal Medicine, 22nd Ed. (2025) - Bilirubin metabolism + Insulin biosynthesis/secretion
Medical Physiology (Boron & Boulpaep) - Beta cell physiology, insulin synthesis
Tietz Textbook of Laboratory Medicine, 7th Ed. - Ketogenesis, HbA1c, diagnosis
Goldman-Cecil Medicine - DKA clinical features and diagnosis

Generate a PDF study guide with all cases for quick revision

Reading File

Running Command

Writing File

Running Command

Your PDF study guide is ready!

MBBS ClinicalCases Jaundice Diabetes

PDF Document · PDF

Here's what's inside the PDF (professionally formatted with colour-coded sections, tables, pathway boxes, and textbook quotes):

Cover Page + Contents Table

Part 1 — 3rd Year MBBS: Clinical Cases

Case J1: Prehepatic Jaundice (Autoimmune Haemolytic Anaemia)
Case J2: Hepatocellular Jaundice (Acute Viral Hepatitis A)
Case J3: Obstructive Jaundice (Carcinoma Head of Pancreas) — Courvoisier's sign
Case J4: Gilbert's Syndrome
Case D1: Type 1 DM / DKA — new onset with full DKA severity criteria table
Case D2: Type 2 DM — incidental detection, metabolic syndrome
Case D3: HHS vs DKA full comparison table
Case D4: Drug-induced liver injury in a diabetic
Case D5: Metformin-associated lactic acidosis

Part 2 — 1st & 2nd Year MBBS: Biochemistry Deep Dives

Full bilirubin pathway with stepwise reaction boxes (heme oxygenase → UGT1A1 → MRP2 → gut)
Neonatal jaundice and kernicterus mechanism
Why pale stools, dark urine, and pruritus in obstruction — with pathway diagram
Insulin biosynthesis: preproinsulin → proinsulin → insulin (gene to granule)
Beta-cell K_ATP channel cascade and sulfonylurea mechanism of action
DKA ketone body formation pathway (HMG-CoA pathway, OAA depletion explained)
HbA1c: Schiff base → Amadori product, with causes of false results

Part 3 — Quick Reference Tables

Master jaundice comparison (prehepatic/hepatocellular/posthepatic)
Bilirubin enzyme defects table (Gilbert's, Crigler-Najjar, Dubin-Johnson)
Type 1 vs Type 2 DM comparison
Ketone bodies reference with the Ketostix exam trap
HbA1c diagnostic ranges with eAG formula

This is a shared conversation. Sign in to Orris to start your own chat.